Plasmid DNA Manufacturing Global Market Report 2024

The plasmid DNA manufacturing market size has grown exponentially in recent years. It will grow from $1.89 billion in 2023 to $2.34 billion in 2024 at a compound annual growth rate (CAGR) of 23.6%. The expansion observed in the historical period can be attributed to several factors. These include the application of plasmid DNA in industrial processes, the utilization of plasmid DNA in creating genetically modified organisms, the production of monoclonal antibodies using plasmid DNA in cell lines, international health initiatives utilizing plasmid DNA, the use of plasmid DNA in bioremediation and other environmental applications, and microbiome studies involving plasmid DNA.

The plasmid DNA manufacturing market size is expected to see exponential growth in the next few years. It will grow to $5.49 billion in 2028 at a compound annual growth rate (CAGR) of 23.7%. The anticipated growth in the forecast period can be attributed to several factors. These include the increasing use of plasmid DNA in the development of DNA vaccines for infectious diseases, the rising adoption of plasmid DNA in the development of antibody-drug conjugates and personalized therapies, the utilization of plasmid DNA in developing cancer treatments, and advancements in intellectual property developments related to plasmid DNA technologies. Major trends expected in the forecast period encompass increased activity in licensing agreements for plasmid DNA technologies, the provision of customized solutions, implementation of cost reduction strategies, utilization of high-throughput screening methods, and the development of scalable manufacturing solutions.

The increasing adoption of gene therapy is poised to drive the expansion of the plasmid DNA manufacturing market in the future. Gene therapy, a medical approach involving the modification or manipulation of genes to treat or prevent diseases, is gaining traction due to advancements in genetic engineering technologies, augmented investment in research and development, successful clinical trials, and the rising incidence of genetic disorders. These factors underscore its potential to offer long-lasting or permanent remedies. Plasmid DNA manufacturing plays a crucial role in gene therapy as it produces the vectors necessary to deliver therapeutic genes into cells, facilitating the treatment of genetic disorders. For instance, data from the American Society of Gene & Cell Therapy reveals a 10% increase in the number of gene therapies in Phase III clinical trials during Q3 2023, marking the first quarterly uptick since Q3 2022. Thus, the growing acceptance of gene therapy is fueling the growth of the plasmid DNA manufacturing market.

Key players in the plasmid DNA manufacturing market are focusing on the development of advanced bioprocessing technologies to enhance the efficiency, scalability, and quality of plasmid DNA production. These technological advancements aim to streamline manufacturing processes, reduce production costs, and ensure compliance with stringent regulatory standards for therapeutic applications. For example, Charles River Laboratories, a US-based pharmaceutical company, introduced the eXpDNA platform in January 2023. This platform integrates advanced bioprocessing technologies, scalable production methods, and stringent quality control measures to deliver high-quality plasmid DNA suitable for therapeutic and clinical applications. Widely utilized in gene therapy, DNA vaccine development, and other biopharmaceutical applications, the eXpDNA platform ensures high yield, purity, and consistency.

In August 2021, Danaher Corporation, a US-based medical equipment manufacturing company, completed the acquisition of Aldevron for $9.6 billion. This strategic acquisition bolsters Danaher's presence in the biotechnology sector by providing access to Aldevron's expertise in genetic material production. Through this acquisition, Danaher aims to support the advancement of genetic treatments and bolster research endeavors within the biotechnology industry, contributing to the development of therapies across diverse applications. Aldevron, a US-based biotechnology company specializing in plasmid DNA, mRNA, and protein manufacturing, enhances Danaher's capabilities in the burgeoning field of gene therapy.

Major companies operating in the plasmid dna manufacturing market are Thermo Fisher Scientific Inc., Eurofins Genomics LLC, Catalent Inc., Charles River Laboratories, Recipharm AB, Kaneka Corp., Genscript Biotech Corporation, Aldevron LLC, Genewiz, OriGene Technologies, Celonic AG, Creative Biogene, Cellectis, Synbio Technologies, VectorBuilder Inc., Altogen Biosystems, Addgene, Andelyn Biosciences, AGC Biologics, VGXI, BioCat GmbH, GeneCopoeia, PlasmidFactory GmbH & Co. KG, Akron Biotech, PackGene Biotech lnc.

North America was the largest region in the plasmid DNA manufacturing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasmid dna manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the plasmid dna manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Plasmid deoxyribonucleic acid (DNA) manufacturing involves producing large quantities of plasmid DNA molecules for various biotechnological applications, including gene therapy, molecular cloning, and recombinant protein production. This process entails cultivating bacterial cells containing the desired plasmid DNA, followed by purification to isolate the plasmid DNA from other cellular components.

The primary grades of plasmid DNA manufacturing include research and development grade, and good manufacturing practice (GMP) grade. Research and Development grade plasmid DNA is primarily intended for laboratory research and early-stage development processes. It is utilized across various development phases such as pre-clinical therapeutics, clinical therapeutics, and marketed therapeutics for treating infectious diseases, cancer, genetic disorders, and other ailments. This type of DNA is essential for various applications including DNA vaccines, cell and gene therapy, immunotherapy, and others.

The plasmid DNA manufacturing market research report is one of a series of new reports that provides plasmid DNA manufacturing market statistics, including the plasmid DNA manufacturing industry global market size, regional shares, competitors with plasmid DNA manufacturing market share, detailed plasmid DNA manufacturing market segments, market trends, and opportunities, and any further data you may need to thrive in the plasmid DNA manufacturing industry. This plasmid DNA manufacturing market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The plasmid DNA manufacturing market consists of revenues earned by entities by providing services such as plasmid design, construction, production, purification, quality control, customization, storage, shipping, and regulatory support. The market value includes the value of related goods sold by the service provider or included within the service offering. The plasmid DNA manufacturing market also includes sales of bioreactors, centrifuges, incubators, chromatography systems, freeze dryers, electrophoresis systems, and microscopes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.